Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden

Objective. The incidence of prostate cancer in Sweden is increasing rapidly, as is treatment with curative intent. Radical prostatectomy (RP) is currently commonly performed, either within or outside large high-volume centres. The aim of this study was to assess the 30-day mortality rate after RP in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scandinavian journal of urology and nephrology 2009, Vol.43 (5), p.350-356
Hauptverfasser:	Carlsson, Sigrid, Adolfsson, Jan, Bratt, Ola, Johansson, Jan-Erik, Ahlstrand, Christer, Holmberg, Erik, Stattin, Pär, Hugosson, Jonas
Format:	Artikel
Sprache:	eng
Schlagworte:	30-day mortality Adult Aged Biological and medical sciences Cause of Death - trends Clinical Medicine Follow-Up Studies Gynecology. Andrology. Obstetrics Humans Kirurgi Klinisk medicin Male Male genital diseases Medical and Health Sciences Medical sciences MEDICIN Medicin och hälsovetenskap MEDICINE Middle Aged Nephrology. Urinary tract diseases Oncology Onkologi Population Surveillance Postoperative Period prostatectomy Prostatectomy - mortality prostatic neoplasms Prostatic Neoplasms - mortality Prostatic Neoplasms - surgery Retrospective Studies Risk Factors Surgery Survival Rate - trends Sweden - epidemiology Time Factors Tumors Tumors of the urinary system Urinary tract. Prostate gland Urologi och njurmedicin Urology and Nephrology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective. The incidence of prostate cancer in Sweden is increasing rapidly, as is treatment with curative intent. Radical prostatectomy (RP) is currently commonly performed, either within or outside large high-volume centres. The aim of this study was to assess the 30-day mortality rate after RP in Sweden. Material and methods. In this nationwide population-based study, all men diagnosed with localized prostate cancer (≤70 years, clinical stadium T1-2, prostate-specific antigen
ISSN:	0036-5599 1651-2065 1651-2065
DOI:	10.3109/00365590902916930